Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 523Neoplasms 436Carcinoma, Non-Small-Cell Lung 409Prostatic Neoplasms 325Colorectal Neoplasms 312Lung Neoplasms 259Multiple Myeloma 226Neoplasm Metastasis 194Leukemia, Myeloid, Acute 180Pancreatic Neoplasms 176Ovarian Neoplasms 174Melanoma 146Squamous Cell Carcinoma of Head and Neck 137Carcinoma, Hepatocellular 117Stomach Neoplasms 114Carcinoma, Renal Cell 114Endometrial Neoplasms 110Recurrence 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Head and Neck Neoplasms 109Lymphoma 108Lymphoma, Non-Hodgkin 104Glioblastoma 104Brain Neoplasms 100Uterine Cervical Neoplasms 95Urinary Bladder Neoplasms 93Hematologic Neoplasms 92Triple Negative Breast Neoplasms 90Glioma 87Leukemia, Lymphocytic, Chronic, B-Cell 86

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × 30 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡